Biosig Technologies (NASDAQ:STEX) Major Shareholder Frank Giustra Buys 1,000,000 Shares of Stock

Biosig Technologies, Inc. (NASDAQ:STEX) major shareholder Frank Giustra acquired 1,000,000 shares of Biosig Technologies stock in a transaction dated Friday, January 23rd. The stock was acquired at an average cost of $3.00 per share, with a total value of $3,000,000.00. Following the completion of the transaction, the insider directly owned 1,178,205 shares of the company’s stock, valued at $3,534,615. This trade represents a 561.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Biosig Technologies Trading Up 7.4%

STEX stock traded up $0.25 on Tuesday, reaching $3.65. 3,070,785 shares of the company were exchanged, compared to its average volume of 1,343,926. The firm has a market capitalization of $542.43 million, a P/E ratio of -2.70 and a beta of 1.48. Biosig Technologies, Inc. has a 12 month low of $0.40 and a 12 month high of $14.11.

Biosig Technologies News Roundup

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Significant insider buying by company insiders — Director Morgan Lee Lekstrom increased his holdings with multiple purchases (totaling ~69,500 shares across Jan. 23–27) and CIO Mitchell Young Williams bought 51,511 shares, signaling management confidence at ~ $3.03–$3.30 per share. This buying often supports near-term demand for the stock. Insider Filing
• Neutral Sentiment: Trading activity is elevated vs. the stock’s average volume, which can amplify price moves while these corporate items digest in the market. (Background volume and price context: MarketBeat STEX page.) MarketBeat STEX
• Negative Sentiment: Streamex (ticker STEX) completed its underwritten offering and the underwriters’ over?allotment was exercised in full, increasing total shares issued and producing roughly $40.25M gross proceeds. The deal materially enlarged the share count, which is dilutive and can weigh on the stock despite the cash infusion. GlobeNewswire: Over-Allotment
• Negative Sentiment: Fresh sell-side/ratings pressure — Weiss Ratings initiated coverage with a “sell (d-)” designation, and the stock’s consensus on MarketBeat remains on the sell side, which could limit upside while investor attention focuses on dilution and fundamentals. MarketBeat: Coverage

Analyst Upgrades and Downgrades

Separately, Weiss Ratings initiated coverage on shares of Biosig Technologies in a research note on Friday. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.